Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Buprenorphine: a primer for emergency physicians.

Karl A Sporer1

  • 1Department of Emergency Services, San Francisco General Hospital, University of California-San Francisco, San Francisco, CA 94110, USA. ksporer@itsa.ucsf.edu

Annals of Emergency Medicine
|April 28, 2004
PubMed
Summary

Buprenorphine, approved for office-based opioid addiction treatment, offers a safer alternative due to its "ceiling effect." This limits respiratory depression and dependence, aiding detoxification and maintenance therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns in California Ambulance Patient Offload Times by Local Emergency Medical Services Agency.

JAMA network open·2024
Same author

Race, Neighborhood Disadvantage, and Prehospital Law Enforcement Handcuffing in Children With Behavioral Health Emergencies.

JAMA network open·2024
Same author

Evaluating the feasibility of prehospital point-of-care EEG: The prehospital implementation of rapid EEG (PHIRE) study.

Journal of the American College of Emergency Physicians open·2024
Same author

Novel Methodology for Linking 9-1-1 Dispatch Categories with a Death Registry: Mortality Rates of Selected Dispatch Categories.

Prehospital emergency care·2024
Same author

Physical restraint use in children with mental and behavioral health emergencies in the prehospital setting.

Journal of the American College of Emergency Physicians open·2023
Same author

Paramedic use of the Physician Order for Life-Sustaining Treatment (POLST) for medical intervention and transportation decisions.

BMC emergency medicine·2022

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Clinical Therapeutics

Background:

  • Buprenorphine's recent FDA approval expands office-based treatment for opioid addiction.
  • Understanding buprenorphine's unique pharmacological profile is crucial for its clinical application.

Purpose of the Study:

  • To detail the pharmacological properties of buprenorphine.
  • To outline its clinical use in opioid addiction treatment, including detoxification and maintenance.
  • To describe potential adverse effects and management strategies.

Main Methods:

  • Pharmacological classification: partial micro opioid agonist, weak kappa antagonist.
  • High micro receptor affinity with slow dissociation, leading to long duration and potent analgesia.
  • Dose-dependent agonist effects plateau, creating a

Related Experiment Videos

  • ceiling effect
  • limiting respiratory depression and analgesic potential.

    • Main Results:

    • Buprenorphine exhibits a favorable safety profile, low physical dependence, and mild withdrawal symptoms.
    • Combination products (buprenorphine/naloxone) and buprenorphine-only formulations are available.
    • Potential for mild precipitated withdrawal in patients with recent illicit opioid use.
    • Acute intoxication presents with mild mental status changes, minimal respiratory depression, and normal vital signs.

    Conclusions:

    • Buprenorphine represents a significant advancement in treating opioid addiction.
    • Its
    • ceiling effect
    • enhances clinical safety compared to full opioid agonists.
    • Careful induction is necessary to avoid precipitated withdrawal; significant intoxication requires observation.